SCHEMBL3765697

SCHEMBL3765697

N#Cc1c(N)sc2c1CCCC2=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 3/20 0.54
ALDH1A1 P00352 9/20 0.53
MAPT P10636 7/20 0.53
GAA P10253 5/20 0.53
HSD17B10 Q99714 4/20 0.53
MAPK1 P28482 3/20 0.53
ALOX15 P16050 3/20 0.53
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
CASP1 P29466 3/20 0.51
POLB P06746 2/20 0.51
PABPC1 P11940 1/20 0.51
KDM4E B2RXH2 5/20 0.50
HPGD P15428 3/20 0.50
RECQL P46063 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.37
MET P08581 1/20 0.37
CASP7 P55210 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1514467 0.74 BPTF (0.92) BPTFALDH1A1MAPTGAAHSD17B10
SCHEMBL24858530 0.72 BPTF (0.54) BPTFALDH1A1MAPTGAAHSD17B10
SCHEMBL3762032 0.72 ALDH1A1 (0.44) BPTFALDH1A1MAPTGAAHSD17B10
SCHEMBL620749 0.71 BPTF (1.00) BPTFALDH1A1MAPTGAAHSD17B10
SCHEMBL3766049 0.70 PIK3CA (0.46) ALDH1A1MAPTHSD17B10MAPK1KMT2A
SCHEMBL1719516 0.69 ALDH1A1 (1.00) BPTFALDH1A1MAPTGAAHSD17B10
SCHEMBL31381502 0.69 BPTF (0.96) BPTFALDH1A1MAPTGAAHSD17B10
SCHEMBL3492367 0.69 ALDH1A1 (0.45) ALDH1A1MAPTGAAHSD17B10MAPK1
SCHEMBL2614831 0.68 ALDH1A1 (1.00) BPTFALDH1A1MAPTGAAHSD17B10
SCHEMBL5360384 0.68 ALDH1A1 (0.38) ALDH1A1MAPTGAAHSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed
EP-1343561-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
EP-0150319-B1 COLOUR-PHOTOGRAPHIC RECORDING MATERIAL WITH A BLUE-GREEN DYE RELEASING COMPOUND, THE COLOUR IMAGE OBTAINED BY MEANS OF THIS DYE AND THE DYE ITSELF Agfa-Gevaert AG (DE) 1987-07-01 EP disclosed
US-4579805-A DIFFUSION TRANSFER AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) 1986-04-01 US disclosed
EP-0150319-A2 Colour-photographic recording material with a blue-green dye releasing compound, the colour image obtained by means of this dye and the dye itself Agfa-Gevaert AG (DE) 1985-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA BPTF 2836/4885ALDH1A1 3061/4885MAPT 790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.